Brintellix is launched as the first new antidepressant drug in five years in Denmark
16 September 2014 | By Lundbeck
...and will be introduced in several other European and International Markets during 2014 and 2015.
List view / Grid view
News
Bristol-Myers Squibb to challenge Merck in skin cancer treatment arena, says GlobalData Analyst
16 September 2014 | By GlobalData
Merck’s Keytruda, which was recently approved in the US to treat patients with advanced melanoma, who have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s Opdivo, says an analyst with research and consulting firm GlobalData...
Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study
16 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with Type 2 Diabetes...
BGI and The Vancouver Prostate Centre announce partnership to create Joint Research Laboratory for advancement of translational cancer research
16 September 2014 | By Alto Marketing Limited
BGI and The Vancouver Prostate Centre announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including personalized oncology...
Cardio3 Biosciences receives approval for the continuation of its chart-1 Phase iii clinical trial from the DSMB
16 September 2014 | By Cardio3 BioSciences
Cardio3 BioSciences SA announces it has received the recommendation of the Data Safety and Monitoring Board (DSMB) to continue the CHART-1 clinical trial according to the original protocol...
Dolomite to launch Meros TCU-100 temperature controller at Lab-on-a-Chip & Microarray World Congress
16 September 2014 | By kdm communications
Microfluidics specialist Dolomite will be launching the Meros TCU-100 at this year’s Lab-on-a-Chip & Microarray World Congress in San Diego, USA, from the 18th to the 19th September...
Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
15 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the multinational RE-VERSE AD clinical trial – the study investigating the emergency reversal of the anticoagulant effect of dabigatran – has been initiated in the UK...
Genetic testing can identify men at six-fold increased risk of prostate cancer
15 September 2014 | By The Institute of Cancer Research, London
Scientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease...
Bone Therapeutics receives clearance for ALLOB® phase II trial in spinal fusion
15 September 2014 | By Bone Therapeutics
Bone Therapeutics’ allogeneic osteoblastic cell therapy product enters the clinic to facilitate spinal fusion in patients with degenerative lumbar disc disease...
Cheaper alternative to licensed drug for treating eye disease has similar side-effects says new Cochrane Review
15 September 2014 | By The Cochrane Library
Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published...
ABSORB II study shows Abbott’s dissolving heart device comparable to the world’s leading heart stent
15 September 2014 | By Abbott
Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE family of DES...
Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA)
15 September 2014 | By Roche
Roche announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy, the advanced form of age-related macular degeneration, a progressive condition which can result in blindness...
International reports reinforce need to redouble China anti-counterfeiting efforts, says global hologram trade body
15 September 2014 | By Issued on behalf of the IHMA by MHW PR Ltd
Millions of fakes pouring into EU, US and Japanese markets...
Lilly announces CYRAMZA™ Phase III second-line colorectal cancer trial meets primary endpoint of overall survival
12 September 2014 | By Eli Lilly and Company
Eli Lilly and Company announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival...
Scientific founder of Intercept Pharmaceuticals joins Tiziana Life Sciences
12 September 2014 | By Tiziana Life Sciences
Tiziana Life Sciences announces the appointment of Professor Roberto Pellicciari to the Company’s Scientific Advisory Board and as a consultant to the Company...
